Product Description
RafaelÕs lead compound, CPI-613¨Ê(devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth. (Sourced from: https://rafaelpharma.com/research-and-development/cpi-613-drug)
Mechanisms of Action: Pyruvate Dehydrogenase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: Fast Track - Acute Leukemia|Acute Myeloid Leukemia|Leukemia|Myeloid LeukemiaFast Track - Pancreatic CancerOrphan Drug - Biliary Tract CancerOrphan Drug - Lymphoma|Burkitt LymphomaOrphan Drug - Sarcoma *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Clear Cell Sarcoma
Phase 1: Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| jRCT2080225264 | P1 |
Completed |
Pancreatic Cancer |
2023-05-31 |
|||
| CCS618 | P2 |
Completed |
Clear Cell Sarcoma |
2023-03-09 |
33% |
2022-11-16 |
Patient Enrollment|Primary Endpoints|Treatments |